





# PRESENTATION OF THE CANCER CLUSTER CLARA

KEY FEATURES OF CANCER R&D  
IN AUVERGNE RHÔNE-ALPES REGION

2017

# CANCER CLUSTER CLARA: A NETWORK OF EXCELLENCE



## Clermont-Ferrand

💡 5% 🏢 1 🎓 2 🏥 2

## Lyon

💡 60% 🏢 42 🎓 3 🏥 2 🌐 1

## Grenoble

💡 30% 🏢 27 🎓 3 🏥 1

## Saint-Étienne

💡 5% 🎓 1 🏥 2



Distribution of  
cancerology  
researchers



Number of companies  
developing cancerology  
products



Universities



University hospitals, cancer treatment  
centers, cancer institutes



International Agency for  
Research on Cancer

International Agency for Research on Cancer




World Health  
Organization




Hospices Civils de Lyon



# PROOF OF CONCEPT - A KEY STEP IN DEVELOPMENT



# PROOF OF CONCEPT PROGRAM



- Call for proposals (yearly)
- Two objectives
  - Proof of Concept of a technology, product or service for the benefit of the patient in Oncology (therapy, diagnostic, quality of life, prevention)
  - Economical development of local companies
- Requirements
  - Medical need in oncology
  - Partnership between academic/clinic team and start-up/SME
  - Auvergne -Rhône-Alpes area
  - Strong medicine & science (IP protected,)
  - Business model for the partner company
- Grant :300 000 €
  - Funding for academic & clinical partners
  - Commitment of private partner to bring (at least) equal amount
- Project duration : 3 years (2 to 3 years)

# LANTHARAD (2009-2012)



Subvention  
409 K€

44 K€



Hybrid radiosensitizer nanoparticles allowing treatment of radio-resistant tumors

- in vivo proof-of-concept of the radio-sensitizing effect of the NP in head and neck cancer

## Impact

- ✓ 1 patent
- ✓ 6 publications
- ✓ 1 spin-off creation in 2016: NH Theraguix

# HEPATOFLUO (2011-2015)

LEAD  
PRODUCT  
MARKETED



Assessment of Indocyanine Green (ICG) as a Near-Infrared Fluorescent Contrast agent for image-guided liver surgery

- Validation of the use of fluorescence in hepatic surgery by use Fluobeam® and ICG
- Optimization of the development of Fluobeam®

## Impact

- ✓ Start-up creation
- ✓ 2,75 M€ fund raised
- ✓ Fluobeam® marketed
- ✓ Turnover: 1,5 M€ (2015)

# TECHNOLOGY TRANSFER, R&D AND OPEN INNOVATION

## Network

with pharmaceuticals companies  
and investors



## Coach

project coordinators



## Fund

public-private partnership projects



Open  
October

## Detect

new projects and foster collaborations



In Grenoble, Dec 7  
Abstract before  
October 31st

## Educate & Train

researchers about industrial transfer  
and development



## CONTACT

**Ophelie PHILIPOT, PhD**

Project officer, R&D & Technology Transfer  
Cancer cluster Lyon Auvergne Rhone-Alps (CLARA)  
Lyon, FRANCE

Tel : +33 (0)4 37 90 17 25

[ophilot@canceropole-clara.com](mailto:ophilot@canceropole-clara.com)

[www.canceropole-clara.com](http://www.canceropole-clara.com)

[@canceroCLARA](#) [#valoCLARA](#)

**ACCÉLÉRATEUR D'AVANCÉES CONTRE LE CANCER**

Sous l'égide de

